Imaging Biometrics wraps up successful Phase I trial of glioblastoma drug

UK‑based biotech company Imaging Biometrics Ltd (LSE: IBAI; OTCQB: IQAIF) has announced the completion of its Phase I clinical trial of gallium maltolate (GaM), an oral treatment designed for recurrent glioblastoma (GBM), one of the most aggressive forms of brain cancer. The study, conducted by Medical College of Wisconsin, involved 26 participants and met its safety and pharmacokinetic targets with no significant adverse events reported. Of these, 24 were evaluated for safety, and 22 showed early signs of efficacy — one patient remains under treatment, highlighting the potential clinical benefit. CEO Trevor Brown described this milestone as “a pivotal step” in the company’s mission to deliver mechanism‑driven therapies for GBM. The drug works by disrupting tumour metabolism via iron‑targeting pathways, and preclinical evidence suggests its use in combination with standard treatments. With Phase I concluded, Imaging Biometrics is now partnering with leading cancer centres to launch a Phase II trial focused on efficacy and broader clinical use. #glioblastoma #braincancer #clinicaltrial #biotech #SlimScan #GrowthStocks #CANSLIM